ETNB 89bio Pharma: Rasio rega marang prakiraan pendapatan
The future P/S for 89bio, Inc. (ETNB) is available as a chart in the GURU.Markets system, where the metric is fixed at , correlating with the implementation of algorithms in drug discovery. The business model relies on the full outsourcing of synthesis and testing. The development strategy excludes mergers, allowing only commercial partnerships with industry behemoths to implement its proprietary developments.
Ringkesan rincian data analitis 89bio Pharma (ETNB)
- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas 89bio, Inc.|ETNB - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal 89bio, Inc.|ETNB - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku 89bio Pharma|ETNB - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan 89bio|Likuiditas cepet 89bio.com
- rincian asil keuangan lan kelipatan valuasi:
ETNB - Penghasilan resik perusahaan|Bathi mangsa ngarep 89bio, Inc.|ETNB - Nilai perusahaan marang bathi resik|Pangali Forward P/E 89bio Corp|ETNB - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan 89bio Pharma|ETNB - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) 89bio|ETNB - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan 89bio.com|ETNB - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep 89bio, Inc.
- indikator volume dodolan lan pendapatan:
Analisis komprehensif perusahaan:89bio ETNB
The forward P/S ratio determines the market value of an asset relative to expected sales, allowing an investor to assess the extent of the premium paid for future cash flows. By analyzing the forward P/S trend, one can understand how the market values the efficiency of the 89bio, Inc. (ETNB) strategy of outsourcing production and trials to external contractors to concentrate resources on developing innovative drugs for metabolic disorders.
Karo sapa 89bio, Inc. saingan
Rasio rega marang prakiraan pendapatan Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan NewAmsterdam Pharma N.V. (NAMS)|Multiplikator forward rega marang pendapatan Soleno Therapeutics Corp SLNO|Rega forward marang dodolan Amicus Therapeutics|Rasio kapitalisasi marang dodolan sing dikarepake agios.com (AGIO)|Structure Therapeutics Inc. - Multiplikator Forward P/S|MDXG: Rasio rega marang prakiraan pendapatan|RZLT: Multiplikator Forward P/S|LXRX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MBX Biosciences Inc|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep altimmune.com ALT|Multiplikator forward rega marang pendapatan AARD (Aardvark Therapeutics)|SGMT (Sagimet Biosciences, Inc.) - Rega forward marang dodolan|Multiplikator Forward P/S BIOA (BioAge Labs Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Biomea Fusion Corp (BMEA)|QNCX - Rasio rega marang prakiraan pendapatan|GUTS (fractyl.com) - Kapitalisasi marang prakiraan pendapatan|VTVT: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Agape ATP|Multiplikator forward rega marang pendapatan PLUR|Synlogic Corp (SYBX) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S LPCN|MTNB - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Spruce Biosciences, Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake GLTO (Galecto Inc)|CTCX - Rasio rega marang prakiraan pendapatan|LUMO (Lumos Therapeutics) - Kapitalisasi marang prakiraan pendapatan|ONVO: Multiplikator Forward P/S|RDUS (radiuspharm.com) - Rasio rega marang prakiraan pendapatan
